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Introduction: Several innate immunity genes are overexpressed in human cancers and their roles remain
controversial. Bone marrow stromal antigen 2 (BST-2) is one such gene whose role in cancer is not clear. BST-2 is a
unique innate immunity gene with both antiviral and pro-tumor functions and therefore can serve as a paradigm
for understanding the roles of other innate immunity genes in cancers.
Methods: Meta-analysis of tumors from breast cancer patients obtained from the Gene Expression Omnibus (GEO)
and The Cancer Genome Atlas (TCGA) datasets were evaluated for levels of BST-2 expression and for tumor
aggressiveness. In vivo, we examined the effect of knockdown of BST-2 in two different murine carcinoma cells on
tumor growth, metastasis, and survival. In vitro, we assessed the effect of carcinoma cell BST-2 knockdown and/or
overexpression on adhesion, anchorage-independent growth, migration, and invasion.
Results: BST-2 in breast tumors and mammary cancer cells is a strong predictor of tumor size, tumor
aggressiveness, and host survival. In humans, BST-2 mRNA is elevated in metastatic and invasive breast tumors.
In mice, orthotopic implantation of mammary tumor cells lacking BST-2 increased tumor latency, decreased primary
tumor growth, reduced metastases to distal organs, and prolonged host survival. Furthermore, we found that the
cellular basis for the role of BST-2 in promoting tumorigenesis include BST-2-directed enhancement in cancer cell
adhesion, anchorage-independency, migration, and invasion.
Conclusions: BST-2 contributes to the emergence of neoplasia and malignant progression of breast cancer. Thus, BST-2
may (1) serve as a biomarker for aggressive breast cancers, and (2) be a novel target for breast cancer therapeutics.Introduction
The oncogenesis of breast cancer involves multiple events,
including genetic and epigenetic alterations in the behavior
of normal and malignant cells, as well as other cells that
interact with cancer cells [1]. Such alterations modulate
the functions of key host genes, which in turn affect cancer
cell behavior including self-sufficiency in growth signals,
adhesion, invasion, motility, and survival. Our understand-
ing of specific genes linked to the development and pro-
gression of mammary cancer is unraveling. These genes
have enabled the development of targeted therapeutics* Correspondence: chioma-okeoma@uiowa.edu
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article, unless otherwise stated.against mammary cancers that are dependent on such
genes. However, the goal of eliminating breast cancer has
not been met partially because not all cancer driver genes
have been identified. In particular, it is not clear how over-
expression of innate immunity genes in cancer cells endow
these cells tumorigenic potential.
Innate immunity is crucial to host defense. However,
some innate immunity genes play paradoxical roles as they
prevent [2] and/or promote [3] cancer through mecha-
nisms that are not well defined. It has been shown that the
innate immunity gene called bone marrow stromal antigen
2 (BST-2), also known as tetherin, CD317, and HM1.24
is overexpressed in several cancers [4-11]. BST-2 is an
interferon-inducible type II transmembrane protein that
functions as a potent nuclear factor kappa binding
(NF-кB) activator [12]. BST-2-mediated NF-кB activation
occurs through the YXY motif on the cytoplasmic domainMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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The activation of NF-кB by BST-2 results in increased
production of immune-inflammatory mediators that may
inhibit viral replication [13], but may also promote
tumorigenesis. In addition to the NF-кB-regulating role,
BST-2 is reputed for its tethering and antiviral functions,
as its overexpression tethers/retains nascent virions on the
surface of infected cells and prevents infection of new tar-
get cells [15-17]. The tetherin function of BST-2 has been
shown to be involved in cell to cell interactions because
BST-2 mediates the adhesion of monocytes to endothelial
cells [18]; a function that could promote intravasation of
immune cells.
Although overexpression of BST-2 tethers virions on the
cell membrane and negatively regulates virus replication,
it is likely that elevated BST-2 expression might positively
influence cancer cell behavior [6,7,9,10,19]. It has been
suggested that increased cancer cell adhesion and resist-
ance to apoptosis in vitro is linked to BST-2 expression
[18,20,21]. However, the functional consequence of BST-2
expression in tumor tissues and cells is completely un-
known and there has been no direct demonstration of the
involvement of BST-2 in breast tumorigenesis.
Given the role of BST-2 in innate immunity - including
its role in NF-кB activation and subsequent transcription
of NF-кB-dependent genes, as well as the presence of high
levels of BST-2 in breast tumors [21], we hypothesized
that BST-2 may promote mammary tumorigenesis. Here,
we studied the clinical consequences of BST-2 expression
in breast tumors, the functional role of BST-2 in mam-
mary tumorigenesis, and the cellular basis for BST-2-
mediated effect on mammary tumorigenesis.
Methods
Cell lines
E0771 (a medullary breast adenocarcinoma cell line from
C57BL/6 mouse strain) was purchased from CH3 Bio-
Systems (Amherst, NY, USA). 4T1 (a mouse mammary car-
cinoma cell line from BALB/c mouse strain) was provided by
Dr. Lyse Norian of the University of Iowa. HMLE (Normal
human mammary epithelial cell line), MCF-7 cells (luminal
A human breast cancer cell line) and MDA-MB-231 cells
(triple-negative human breast cancer cell line) were kindly
provided by Dr. Weizhou Zhang of the University of Iowa.
Animals
Five-week-old C57BL/6NCr and BALB/cAnNCr female
mice were used. Mice were sacrificed when they became
moribund. Tumor volume (TV) was calculated as: TV =
0.5(length*width2) [22]. Tumor latency was calculated
as the number of tumor-free injected mice/number of
injected mice × 100. To assess morbidity, the following
clinical score ranking was used: (0) no abnormal clinical
signs, (1) ruffled fur but lively, (2) ruffled fur, activity levelslowing, sick, (3) ruffled fur, eyes squeezed shut,
hunched, hardly moving, very sick, (4) moribund and
(5) dead [23]. Experiments involving mice were ap-
proved by the University of Iowa Animal Care and Use
Committee (IACUC).
Mice injections and live animal imaging
Orthotopic mammary tumors were generated by implant-
ing 1.5 × 105 cancer cells in 200 μl of phosphate-buffered
saline (PBS) into the mammary fat pad of five-week-old
female mice. Prior to imaging, mice were anesthetized,
weighed and injected intraperitoneally with D-luciferin.
Mice were imaged using the Xenogen IVIS three-
dimensional optical imaging system (Caliper Life Sciences,
Hopkinton, MA, USA). Luciferase was quantified with
Living Image Software (Caliper Life Sciences).
Histology
Gastrointestinal samples were rolled for processing to
allow visualization of mesenteric tumors. Fixed tissues
were paraffin embedded, sectioned at 4 μm, and stained
with hematoxylin and eosin (H&E). Spleen and lung sec-
tions were imaged using a BX51 Olympus microscope
(Olympus, Tokyo, Japan). Gastrointestinal slides were
scanned with an Aperio ScanScope CS (Aperio Technolo-
gies, San Diego, CA, USA).
Lentiviral transduction
E0771 and 4T1 cells were stably transduced with a con-
struct expressing LV-CMV-firefly luciferase or an empty
vector construct using lipofectamine following the ma-
nufacturer’s instructions (Life Technologies, Carlsbad, CA,
USA). Stable transfectants were then transduced with len-




TTCTCAAGCTTTTTG; or a non-targeting shControl:
CCGGCAACAAGATGAAGAGCACCAACTCGAGTT
GGTGCTCTTCATCTTGTTGTTTTT using a previously
described protocol [17]. Stable cells were generated by
selection with the appropriate drug. The short hairpin
RNA (shRNA) constructs were purchased from Sigma-
Aldrich (St Louis, MO, USA) (SHCLND-NM_198095)
and lentiviral particles were generated at the Gene Transfer
Vector Core at the University of Iowa.
Flow cytometry
Cell monolayers were washed with PBS and treated with
Versene (Life Technologies). Single cells were stained with
fluorescein isothiocyanate (FITC)-conjugated anti-mouse
BST-2 (eBioscience, San Diego, CA, USA), allophyco-
cyanin (APC)-conjugated anti-human BST-2 (BioLegend,
San Diego, CA, USA), and appropriate immunoglobulin
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were incubated with a fluorescent intercalator - 7-
aminoactinomycin D (7-AAD) (BioLegend) at 4°C for
30 minutes to assess cell viability. Stained cells were quan-
tified using a FACSCalibur flow cytometer (BD Bio-
sciences, San Jose, CA, USA). At least 10,000 events were
collected per sample. Fluorescence-activated cell sorting
(FACS) data were analyzed by Flowjo software (TreeStar,
Ashland, OR, USA).
Reverse transcriptase quantitative real-time PCR (RT-qPCR)
Isolation of RNA was accomplished using the RNeasy
mini kit (Qiagen, Venlo, Netherlands) according to the
manufacturer’s instructions. Equivalent amounts of DNase
I (Qiagen)-treated RNA were reverse-transcribed with
a high-capacity cDNA reverse transcription kit (Applied
Biosystems, Carlsbad, CA, USA). cDNA was amplified with
target-specific primers (GAPDH-Forward: 5′-CCCCTTCA
TTGACCTCAACTACA-3′, Reverse: 5′-CGCTCCTGGA
GGATGGTGAT-3′; mouse BST-2-Forward: TCAGGAG
TCCCTGGAGAAGA, Reverse: ATGGAGCTGCCAGAG
TTCAC; human BST-2 RT2 qPCR Primer Assays (SA-
Biosciences, Frederick, MD, USA). RT-qPCR was carried
out with an ABI 7500 FAST thermal cycler (Applied
Biosystems) as previously described [24].
Western blot
Western blots were performed as previously described [24].
Blots were probed with anti-BST-2 (Abcam, Cambridge,
UK) and anti-GAPDH (Santa Cruz Biotechnology, Dallas,
TX, USA) primary antibodies and appropriate IRDye sec-
ondary antibodies were used. Band detection and quantifi-
cation were carried out with the Odyssey Infrared Imaging
System (LI-COR Biosciences, Lincoln, NE, USA).
MEF adhesion assay
Murine embryonic fibroblasts (MEFs) were grown to con-
fluency in 6-well plates. Equivalent numbers (150,000) of
cancer cells labeled with PKH67Green fluorescent cell
linker, following the manufacturer’s instructions (Sigma-
Aldrich), were added to the MEF monolayer and allowed to
incubate for 8 hours. Non-adhered cells were washed off
and adhered cells imaged. Image J (NIH, Bethesda, MD,
USA) was used to quantify the number of PKH67Green-
positive cells. In parallel, luciferase-expressing cancer cells
were added to MEFs monolayers in 6-well plates for
8 hours. Non-adhered cells were washed off and adhered
cells were treated with D-luciferin and imaged using IVIS.
For luciferase assay, cancer cells plated in 96-well plate
were used for quantitation of luciferase bioluminescence.
Collagen and fibronectin adhesion assay
Ninety-six-well plates were coated with 50 μg/ml of col-
lagen or fibronectin. Plates were incubated at 37°C for2 hours. Nonspecific sites were blocked with 40 μl of
2 mg/ml bovine serum albumin (BSA) in PBS. Wells were
washed once with PBS. Cancer cells were labeled with
PKH67 Green fluorescent cell linker, following the manu-
facturer’s instructions (Sigma-Aldrich). Labelled cells were
added to pre-coated wells (20,000 cells/well) and allowed
to adhere for 4 hours. Non-adhered cells were washed off
with PBS and plates were read at 485 nm/535 nm (excita-
tion/emission) wavelengths using a Tecan Infinite M200
Pro plate reader (Tecan, Maennedorf, Switzerland). Values
are represented as relative fluorescence unit.
Scratch assay
Confluent monolayers of cancer cells plated in 12-well
plates were scratched using a pipette tip. Fresh medium
was added to the wells. Cells were allowed to migrate for
0, 6 or 24 hours before fixation (4% paraformaldehyde
(PFA) for 45 minutes). Fixed cells were washed (1 ×
PBS) and imaged with a Nikon Eclipse Ti microscope
adjusted with a Nikon digital sight camera (Nikon,
Tokyo, Japan). Images were processed and migrated cells
counted using Image J software.
Boyden chamber assay
The apical chamber of 24-well cell culture inserts (Merck
Millipore, Billerica, MA, USA) were seeded with previ-
ously starved sh137, sh413 or shControl transduced E0771
cells (150,000) in serum-free medium. Culture medium
containing 30% FBS was added to the basal chamber of
the unit and cells were allowed to migrate through the
membranous barrier for 20 hours at 37°C. Non-migrated
cells were washed off, migrated cells were fixed with 4%
PFA for 5 minutes, washed twice with 1 × PBS, perme-
abilized with 100% methanol for 25 minutes, labeled with
Giemsa stain (for 15 minutes at room temperature) and
imaged using a Nikon Eclipse Ti microscope adjusted with
an X-cite series 120 LED fluorescence microscope light
source and a Nikon digital sight camera. Images were
processed using Image J software. Cells from five different
fields were counted and averaged.
Cell invasion assay
The apical chamber of 24-well cell culture inserts (Merck
Millipore) were coated with 3 mg/ml of Matrigel (100 μl)
(Sigma-Aldrich) and allowed to solidify for 5 hours. A
total of 100,000 sh413- or shControl-transduced E0771 or
4T1 cells in serum-free medium were plated on top of the
Matrigel layer. Culture medium containing 10% FBS and
5 μg/ml fibronectin (adhesive substrate) (Sigma-Aldrich)
was added to the basal chamber of the unit (600 μl) and
cells were allowed to invade through the membranous
barrier for 24 hours at 37°C. Noninvasive cells were
washed off; invasive cells were fixed with 4% PFA, perme-
abilized with 100% methanol, labeled with Giemsa stain
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ages were processed using Image J software. Cells from
five different fields were counted and averaged.
MTT assay
A total of 5,000 cells stably expressing sh137, sh413, or
shControl were plated in 96-well plates. Cells were then
incubated with 5 mg/ml MTT reagent for 3.5 hours
followed by addition of MTT solvent (0.1% NP-40 and
4 mM HCl in isopropanol) and rocking for 15 minutes.
Absorbance at 590 nm was read using a Tecan Infinite
M200 Pro plate reader.
BrdU assay
A total of 5,000 cells were plated in 96-well plates for
24 hours. Bromodeoxyuridine or 5-bromo-2′-deoxyuridine
(BrdU) (Calbiochem, Billerica, MA, USA) assay was car-
ried out according to the manufacturer’s instructions. Ab-
sorbance at 450 nm was read using a Tecan Infinite plate
reader. In parallel, 150,000 cells were plated in 24-well
plates for 24 hours. Cells were incubated with BrdU label
(1:2000) for 20 hours, treated with a fixative/denaturing
solution (30 minutes) and incubated with an anti-BrdU
antibody (1:1000) and rat anti-mouse BST-2 antibody
(1:200, eBioscience) for 1 hour at room temperature. Cells
were washed and incubated with Alexa Fluor 594 anti-rat
(Invitrogen, Waltham, MA, USA) and Alexa Fluor 488
anti-mouse (Invitrogen) secondary antibodies for 30 mi-
nutes at room temperature. Cells were stained with 4′,6-
diamidino-2-phenylindole (DAPI)-containing Vectashield
(Vector Laboratories, Burlingame, CA, USA) and im-
aged using a Zeiss 710 confocal microscope (Carl Zeiss,
Oberkochen, Germany). Images were processed using Image
J software. BrdU label, fixative/denaturing solution, and
anti-BrdU antibody were from BrdU (Calbiochem) assay.
Transformation assay
Agar was mixed in Roswell Park Memorial Institute
medium (RPMI) with 20% FBS. A total of 500 μl of 0.5%
agar was added to 24-well plate and allowed to solidify.
Cells were plated at 1,250 cells/well in 500 μl of 0.35%
agarose. Some 250 μl of the appropriate growth medium
was added on top of the agarose layer. Growth medium
was replaced twice a week. Colonies were stained with
crystal violet and imaged. Colonies from five different
fields were counted and averaged.
Meta-analysis
Three publically available Gene Expression Omnibus
(GEO) datasets GSE4922 [25], GSE21422 [26] and
GSE10797 [27] were used to analyze BST-2 expression
with respect to tumor size, breast cancer classification and
tumor type, respectively. From the GSE4922 dataset, only
data from the Affymetrix Human Genome U133A Arraywere used (Affymetrix, Santa Clara, CA, USA). From these
data, only patients from Uppsala (Sweden) who had BST-2
transcript expression from tumor and tumor size data
were considered. Patients who had tumor size values
higher than 100 mm (one patient, outlier) were excluded.
The publicly available GSE21422 dataset was used to de-
termine whether there was a relationship between BST-2
expression and breast cancer classification. BST-2 ex-
pression was measured by GeneChip Robust Multiarray
Averaging (GC-RMA). All data points were used. The
publicly available GSE10797 dataset was used to deter-
mine whether BST-2 transcript levels are high in multiple
cell types (epithelial and stromal cells) that form the
tumor environment. In addition, the publicly available
breast-invasive carcinoma (BRCA) data from The Cancer
Genome Atlas (TCGA) data portal was used to evaluate
the expression of BST-2 and patient survival. The data
were downloaded through the University of Iowa’s Insti-
tute for Clinical and Translational Science website [28]
and through the University of California, Santa Cruz Can-
cer Browser. Patients who only had BST-2 expression data
available from tumor tissues and not normal tissue or vice
versa were excluded from the analysis of BST-2 levels in
normal vs tumor tissues (100 patients were analyzed). For
BST-2 level analysis in different cancer subtypes, primary
tumor data was segregated on their different breast cancer
subtypes and BST-2 levels were plotted. For survival ana-
lysis, primary tumor data were segregated based on BST-2
expression levels. The top 120 (highest BST-2 expressing
patients - High) and bottom 120 (lowest BST-2 expressing
patients - Low) samples were used for this analysis. A
Kaplan-Meier plot (GraphPad Prism 6, GraphPad Soft-
ware, San Diego, CA, USA) was used to analyze survival
of patients expressing different levels of BST-2 in their
primary tumor tissues. Median overall survival time and
area under the curve (AUC) were calculated using the
GraphPad Prism 6 software.
Statistics
Statistical analysis of significant differences was queried
using the GraphPad Prism 6 software. Kaplan-Meier
survival plots were analyzed with the Gehan-Breslow-
Wilcoxon test using the GraphPad Prism 6 software. A
probability (P) value of 0.05 or lower was considered
significant.
Results
BST-2 expression in breast tumor is associated with
tumor size, tumor aggressiveness, and host survival
We studied BST-2 expression in different human breast
cancer cells compared to normal mammary epithelial
cells. Normal mammary epithelial cells did not express
high BST-2, however, cancer cell lines exhibited high
levels of BST-2 mRNA (Figure S1A in Additional file 1)
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with a previous report [10], and suggestive of a potential
role in mammary oncogenesis.
Meta-analysis of large-scale human breast cancer data
from the GEO and TCGA was used to assess the level of
BST-2 mRNA in breast tumors. We compared BST-2
expression in paired normal breast tissues versus resected
BRCAs from subjects with known clinical outcomes. BST-2Figure 1 BST-2 mRNA is prevalent in highly aggressive tumors and as
paired tumor versus normal breast tissues from The Cancer Genome Atlas
scatter plot and heat map show that BST-2 is significantly elevated in tumo
BST-2 in tumor tissues of patients bearing different subtypes of invasive bre
tumors subtypes with the exception of the basal subtype. (C) BST-2 expres
from GSE4922 was segregated into three BST-2 expression levels (relative u
(D) Tumor size in patients with low, intermediate, or high levels of BST-2 is
signal scores from healthy, ductal carcinoma in situ (DCIS), and invasive duc
(F) BST-2 levels from normal, primary tumors (tumors), and metastatic tumo
(G) Kaplan-Meier survival analysis using TCGA (BRCA) primary tumor sample
between low BST-2 and patient survival. The median overall survival (OS) ti
(H) Mammary epithelial and stromal cells obtained from normal and invasi
in cancerous epithelial cells but not in cancerous stromal cells. In all panels
levels acquired from TCGA and Gene Expression Omnibus (GEO) datasets a
standard deviations and significance was taken at P <0.01**. ns = not signifiexpression was significantly higher in tumor tissues com-
pared to their paired normal breast tissues (Figure 1A).
Stratification of TCGA data into different tumor subtypes
showed that compared to normal tissues, BST-2 expression
was significantly elevated in all tumor subtypes analyzed
with the exception of the basal subtype, where the
difference did not reach statistical significance (Figure 1B).
Of note, the high-grade luminal B tumors expressed moresociates with patients’ poor survival. (A) RNA-seq data (n = 100) of
(TCGA) breast-invasive carcinoma (BRCA) data portal presented as
r tissues compared to matched normal breast tissues. (B) Levels of
ast carcinomas show that BST-2 is upregulated in different breast
sion in tumors from Uppsala (Sweden) breast cancer patients obtained
nits): low = 6.0 to 7.5, intermediate = 7.5 to 9.0, and high = 9.0 to 11.0.
shown. (E) BST-2 GeneChip Robust Multiarray Averaging (GC-RMA)
tal carcinoma (IDC) tumor-bearing patients obtained from GSE21422.
rs (metastatic) of patients bearing invasive breast cancer (TCGA).
s segregated into high and low BST-2 levels show a significant link
me and the area under the curve (AUC) for each group are shown.
ve breast cancer patients (GSE10797) show elevated BST-2 expression
, numbers correspond to P values. The relative units for BST-2 RNA
re SEM-normalized and centralized log2(x + 1). Error bars represent
cant.
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dermal growth factor receptor 2 (HER2)+, and basal type
(Figure 1B).
Large breast tumors have higher BST-2 expression com-
pared to smaller tumors (Figure 1C and D) as revealed by
meta-analysis of human breast cancer data using the GEO
dataset GSE4922 [25]. Separation of the data into low,
intermediate, and high BST-2 levels showed that subjects
whose tumors had high BST-2 (Figure 1C) had strikingly
larger tumors (Figure 1D) compared to the tumor masses
in subjects with intermediate and low BST-2 (Figure 1C
and D). These findings were consistent with the premise
that high BST-2 levels may be predictive of tumor aggres-
siveness and reduced patient survival. We therefore investi-
gated this possibility using the GEO dataset GSE21422 [26]
containing BST-2 mRNA expression data from normal
breast tissues and tumor tissues from ductal carcinoma in
situ (DCIS) and invasive ductal carcinoma (IDC). As ex-
pected, BST-2 expression was higher in the most aggressive
form of breast cancer, IDC, compared to DCIS (Figure 1E).
Additionally, analysis of BST-2 expression profile with
TCGA dataset segregated into normal, primary tumor, and
metastatic tumor revealed that levels of BST-2 in meta-
static tumors were highly elevated compared to primary
tumors (Figure 1F). Furthermore, Kaplan-Meier model
showed that subjects with high tumor BST-2 had signifi-
cantly reduced survival than those whose tumors had low
BST-2 expression (Figure 1G). While patients bearing high
BST-2-expressing tumors had median overall survival (OS)
time of 2,469 days and AUC of 285,364, subjects with low
BST-2-expressing tumors had OS of 3,188 days and AUC
of 386,186. These data suggest that BST-2 expression is a
strong predictor of survival.
Mammary cancers are epithelial neoplasms and epithelial/
stromal interactions are critical in mammary cancer devel-
opment and progression. To probe into the source of BST-2
in breast tumors, the GEO dataset GSE10797 [27] was used
to investigate the pattern of BST-2 expression in epithelial
cells versus the surrounding stromal cells. There was no dif-
ference in BST-2 levels between stromal cells from tumor
and normal mammary tissues (Figure 1H). In contrast,
BST-2 expression was significantly higher in epithelial cells
from tumor compared to epithelial cells from normal breast
tissues (Figure 1H).These data suggest that epithelial cell-
intrinsic BST-2 may be a significant contributor of elevated
BST-2 in tumor tissues. Together, these results indicate that
BST-2 is most prevalent in extremely aggressive tumors and
associates with patients’ poor survival.
Suppression of BST-2 expression in mammary cancer cells
prolongs time to primary tumor formation and reduces
tumor mass
To establish a system to analyze the functional implica-
tion of BST-2 expressed in cancer cells (Figure S2A inAdditional file 2), we suppressed BST-2 expression in
two murine mammary cancer epithelial cell lines, E0771
cells [29] and 4T1 cells [30]. E0771 cells are syngeneic to
C57BL/6 mice while 4T1 cells are syngeneic to BALB/c
mice. These models resemble human breast cancer
with respect to progression and metastasis [29,30]. Using
BST-2-targeting shRNA (sh137 and/or sh413), we effi-
ciently downregulated BST-2 expression in E0771 and
4T1 cancer cells (Figures S2B to S2E in Additional file 2).
A non-targeting shRNA (shControl) was used as control.
Both BST-2-targeting shRNA constructs reduced BST-2
expression; but sh413 more efficiently suppressed BST-2.
Consequently, sh413-expressing cells were used in all
in vivo studies.
To determine the effect of BST-2 in primary mammary
tumor development, we inoculated BST-2-expressing
shControl and BST-2-suppressed sh413 4T1 cells into
the mammary fat pads of BALB/c mice and evaluated
tumor growth. 4T1 cells formed primary tumors in the
mammary fat pad prior to metastasis [30]. We observed
increased mammary tumor latency (Figure 2A) and de-
layed mammary tumor onset (Figure 2B) in mice im-
planted with BST-2-suppressed sh413 cells compared to
shControl cells. Tumor volume over time was signifi-
cantly lower in sh413 tumors compared to shControl tu-
mors (Figure 2B). Because 4T1 cells were tagged with
luciferase, we tracked cancer cells in vivo by IVIS im-
aging. As expected, luciferase intensity (photons/sec)
was much lower in mice implanted with sh413 cells
compared to shControl-implanted mice at the site of in-
jection (Figure 2C). Inoculation of mice (n = 15) with
BST-2-expressing shControl cells resulted in massive
mammary tumors with an average tumor mass of 1.11 g
± 0.24 (Figure 2D). This result was in stark contrast to
mice (n = 15) inoculated with BST-2-suppressed sh413
cells that developed significantly smaller tumors aver-
aging 0.37 g ± 0.12 in weight (Figure 2D).
The effect of BST-2 in tumor development was also evi-
dent in the E0771-C57BL/6 model (Figure S3 in Additional
file 3). E0771 cells are highly metastatic [29]. Expression of
BST-2 in E0771 cells had a tumor-enhancing effect similar
to the one observed with the 4T1 cells. BST-2-expressing
E0771 cells (shControl) showed significant decrease in
tumor latency compared to BST-2-suppressed E0771 cells
(sh413) (Figure S3A in Additional file 3). Together, these
data suggest that downregulation of BST-2 expression in
breast cancer cells delays mammary tumor onset and may
impair the ability of primary tumors to thrive.
Knockdown of BST-2 in cancer cells decreases metastases
to the lung and other distal sites
E0771 and 4T1 cells metastasize to liver, bone, lung, and
intestine [29,31]. Thus, we investigated whether BST-2
enhances the metastatic potential of primary tumor cells.
Figure 2 Suppression of BST-2 in cancer cells increases tumor latency and decreases tumor mass in vivo. (A) Knockdown of endogenous
BST-2 expression in 4T1 cells increases tumor latency computed as (number of tumor-free injected mice/number of injected mice) x100.
(B) Tumor volume (TV) computed as TV = 0.5 (length*width2) over time is significantly reduced when BST-2 is suppressed in 4T1 cells. (C) Tumor
cells tracked in vivo with IVIS imaging system show significant reduction in luciferase expression in BST-2-suppressed sh413 compared to BST-2-
expressing shControl injected mice. (D) Loss of BST-2 in cancer cells reduced tumor mass. Tumor weight (numbers, g) and gross images obtained
at necropsy are shown. All mice implanted with 4T1 shControl or sh413 cells developed mammary tumors with variation in size. Numbers
represent average ± SEM. Scale bar = 5 mm.
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shControl 4T1luc cells showed early onset and progressive
increase in bioluminescence. The increase in biolumines-
cence signal intensity over time suggests progression and
metastasis of cancer (Figure 3A, upper panel, Figure 3B,
left, middle panel). Indeed, BST-2-expressing shControl
cells formed primary tumors quickly and developed meta-
static lesions that could be detected by bioluminescence
imaging [32]. In striking contrast, BST-2-suppressed 4T1
cells (sh413) exhibited delayed onset of luciferase biolumin-
escence and disappearance of expression as measured overFigure 3 Down-modulation of BST-2 in cancer cells reduces mammar
in vivo with IVIS imaging at different time points. Images show higher lucif
sh413-injected mice. (B) Representative luciferase bioluminescence accomp
of uninjected (upper panel), shControl-implanted (middle panel), and sh413
tumors (middle column) and intestinal/mesenteric tumors (right column). S
mesentery plotted as average of all mice. (D) Representative intestine/mes
confirming increased mesenteric tumors (arrows) in shControl mice compa
by an asterisk (not to be confused with a tumor mass). (E) Representative g
are pointing to tumors. (F) Representative gross images of lungs showing
(G) Percent incidence of liver and lung metastases. (H) Lung histology from
from the 4T1 shControl mice had multiple large tumors (tumors demonstra
alveolar spaces by neutrophils (yellow arrows). Boxed regions are shown at
(lower right). Error bars represent standard deviations and significance was45 days (Figure 3A, lower panel; Figure 3B, left, bottom
panel). Unlike shControl-implanted mice that developed
severe abdominal hemorrhage and intestinal/mesenteric
tumors (Figure 3B, center, middle and right panels), sh413-
implanted mice did not develop hemorrhage and had few
intestinal/mesenteric tumors (compare Figure 3B, un-
injected - upper panel with Figure 3B, sh413-injected -
lower panel). Metastasis to the intestine and mesentery were
significantly reduced from about 21 tumors in shControl
mice (Figure 3B, middle right panel and Figure 3C) to six
tumors in sh413 mice (Figure 3B, bottom right panel andy cancer metastases. (A) Representative images of tumor cells tracked
erase bioluminescence in 4T1 shControl-injected mice compared to
anied with abdominal and gastrointestinal tract (GI tract) gross images
-implanted mice (lower panel). Arrow heads point to mammary
cale bar = 5 mm. (C) Number of secondary tumors in intestine/
entery histology images from 4T1 shControl and sh413-injected mice
red to sh413-injected mice. A mesenteric lymph node is demarcated
ross liver images of 4T1 shControl and sh413-injected mice. Arrows
visible pulmonary nodules (arrows) in shControl-implanted mice.
shControl (upper left) and sh413 (upper right) injected mice. Lung
ted by asterisk) and marked infiltration of the alveolar septa and
higher magnification (40X) for shControl (lower left) and sh413
taken at P <0.01**.
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mesentery tumors in shControl-implanted mice compared
to sh413-implanted mice (Figure 3D, arrows). These
findings were confirmed with the highly metastatic E0771
cells. Mice (n = 10) implanted with BST-2-expressing
E0771 cells (shControl) had higher bioluminescence and
increased intestinal/mesenteric tumors compared to mice
implanted with BST-2-suppressed sh413 cells (Figures S3B
to S3D in Additional file 3).
Importantly, gross images showed that compared to
sh413 cells, shControl cells resulted in significant metasta-
ses to the liver (Figure 3E) and lung (Figure 3F). Lungs
from shControl-implanted mice were laden with pulmon-
ary nodules, suggesting pulmonary metastases (Figure 3F,
arrows). The incidence of metastases to the liver was 86%
and 46%, and 80% and 40% to the lung for 4T1 shControl
and sh413 cells respectively (Figure 3G). Similar trends in
liver and lung metastases were observed with E0771 cells
(Figure S3E in Additional file 3). Furthermore, histologic
analyses confirmed large metastatic nodules in the lung of
mice implanted with 4T1 shControl cells (Figure 3H, as-
terisk). Additionally, there were clustered and scattered
tumor cells throughout the lung interstitium with marked
infiltration of neutrophils within the alveolar septa and
alveolar spaces of lungs from shControl-injected mice
(Figure 3H, arrows).
To test whether the reduced metastasis observed in
mice bearing tumors from BST-2-suppressed cells reflect
a delay in metastasis due to delayed primary tumor growth
and differences in tumor size, we performed a linear re-
gression analysis for correlation between primary tumors
and metastatic growth. However, we found no correlation
between primary tumor and lung or primary tumor and
intestinal/mesentery metastases in our mouse models (not
shown). These results show that BST-2 expression pro-
motes mammary tumor metastasis to distal sites.
BST-2 expression in mammary cancer cells is associated
with poor clinical outcome and significant morbidity in
tumor-bearing mice
Pronounced effect on morbidity was observed in mice
bearing shControl-induced tumors compared to their
counterparts bearing sh413-induced tumors. Specifically,
mice implanted with BST-2-expressing 4T1 cells devel-
oped hypothermia more rapidly and to a higher extent
than mice implanted with BST-2-suppressed sh413. Ruf-
fled hair, shallow breathing, and prostration were observed
in shControl-implanted mice but not in sh413-implanted
mice (Figure 4A). Furthermore, mice implanted with BST-
2-expressing shControl 4T1 cells developed malignant as-
cites (Figure 4B, middle panel) and severe splenomegaly
(Figure 4C, middle panel, inset). Remarkably, 14 out of 15
mice implanted with BST-2-suppressed 4T1 cells (sh413)
were spared of ascites (Figure 4B, compare left and rightpanels) and splenomegaly (Figure 4C, compare left and
right panel insets). Grossly, spleens from shControl mice
were markedly enlarged (Figure 4C, inset). Histologically,
the splenic red pulp of shControl-implanted mice was
markedly expanded by increased immature and mature
granulocytes indicative of increased granulopoiesis
(Figure 4C, shControl, lower panel). In contrast, there was
a slight increase in red pulp granulocytes in the spleen of
sh413-bearing mice (Figure 4C, sh413, lower panel).
Similar to the 4T1 model, clinical manifestations of
disease were delayed in BST-2-suppressed sh413 E0771-
bearing mice (Figure S4A in Additional file 4). Suppres-
sion of BST-2 in E0771 cells prevented the development
of malignant ascites in all (n = 10) sh413 bearing mice
compared to shControl-bearing mice (Figure S4B, upper
panel in Additional file 4). Moreover, BST-2-suppressed
E0771 (sh413)-bearing mice did not develop shock
(assessed by the appearance of pale digits on forelimbs)
as was observed in all E0771 shControl-bearing mice
(Figure S4B, lower panel in Additional file 4) and as pre-
viously shown in the E0771 model [29]. These results
show that expression of BST-2 in cancer cells accelerates
disease progression in tumor-bearing mice.
BST-2-expression in cancer cells results in poorer survival
of tumor-bearing mice
Because human breast cancer patients bearing tumors
with high BST-2 mRNA have lower survival, we directly
evaluated the role of BST-2 expression in cancer cells on
the survival of tumor-bearing mice. Kaplan-Meier survival
curve analysis reveals that mice implanted with BST-2-
suppressed sh413 4T1 or E0771 cells have a statistically
significant prolongation in survival compared with BST-2-
expressing shControl-implanted mice (Figure 4D (4T1)
and Figure S4C (E0771) in Additional file 4). Improvement
in survival was more pronounced in the 4T1 model be-
cause all (n = 15) mice implanted with 4T1 shControl cells
died on average 25 days post implantation. Surprisingly,
14 out of 15 mice implanted with 4T1 sh413 cells survived
and were euthanized at the end of the experiment (day
45). One out of 15 4T1 sh413-implanted mice was sacri-
ficed on day 37 post implantation due to tumor-associated
morbidity (Figure 4D). The OS and AUC for 4T1
shControl-bearing mice were 28 days and 2,345 compared
to sh413-bearing mice with undefined OS and 3,900 AUC.
Additionally, mice implanted with E0771 shControl cells
died at approximately 16 days post implantation compared
to their E0771 sh413 cells-implanted counterparts that
averaged 23 days post implantation (Figure S4C in
Additional file 4). The OS and AUC of E0771 shControl
mice were 16 days and 1,965 respectively, while E0771
sh413-implanted mice have 23 days OS and 2,679 AUC.
Together with the human survival data presented in
Figure 1G, our results support the premise that BST-2
Figure 4 BST-2 expression in cancer cells is a strong prognostic factor for morbidity and overall survival. (A) Clinical score plot of mice
implanted with 4T1 BST-2-expressing shControl and BST-2-suppressed sh413 cells. Clinical signs were scored as follows: 0 = no abnormal clinical signs;
1 = ruffled fur but lively; 2 = ruffled fur, activity level slowing, sick; 3 = ruffled fur, eyes squeezed shut, hunched, hardly moving, very sick; 4 =moribund;
5 = dead [23]. (B) Representative gross images of the abdomen of uninjected (left), shControl-implanted (middle), and sh413-implanted (right) mice.
Arrow points to metastatic ascites (middle panel). (C) Representative splenic gross images (top panel insets) and spleen histology at low magnification
(4X, top panel). Boxed regions are shown at higher magnification (60X) from uninjected (left panel), shControl (middle panel), and sh413 (right panel)
injected BALB/c mice (bottom panels). There was marked expansion of red pulp due to granulocytic hyperplasia in the shControl spleen with slightly
increased number of granulocytes in the red pulp of the sh413 spleen. Scale bar = 5 mm. (D) Kaplan-Meier survival plot of mice implanted with
BST-2-expressing shControl and BST-2-suppressed sh413 4T1 cells. Numbers are P values and error bars represent standard deviations. Median overall
survival (OS) time and the area under the curve (AUC) are shown for each group.
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host survival.
Intrinsic BST-2 in mammary cancer epithelial cells
modulates cancer cells adhesion
The striking effects of BST-2 on tumor growth and me-
tastasis led us to define the cellular basis for BST-2 ef-
fect on breast tumorigenesis. One characteristic feature
of cancer cells is their ability to adhere to and recruit
other cells, such as cancer-associated fibroblasts (CAFs)
to promote formation of primary tumors [33]. To deter-
mine the role of BST-2 in cancer cell adhesion, E0771
cells with varying BST-2 levels were labeled with the
fluorescent cell linker PKH67Green dye and added onto
confluent monolayers of MEF. We found that cancer cell
BST-2 facilitated cancer cell adhesion to fibroblasts asrevealed by confocal microscopy (Figure 5A) and Image
J quantification (Figure 5B) of PKH67Green + cells ad-
hered to MEFs. Large numbers of the BST-2-expressing
(shControl) adhered to fibroblasts compared to cells
with intermediate BST-2 (sh137) and low BST-2 (sh413)
respectively. In parallel, a similar experiment was per-
formed with luciferase expressing shControl or sh413
cancer cells added onto confluent MEFs. Consistent with
the PKH67Green result, suppression of BST-2 decreased
the ability of cancer cells to adhere to supporting cells.
Compared to shControl cells, lower luciferase biolumin-
escence was observed in wells containing sh413 both in
a luciferase assay (Figure 5C) and by IVIS 200 imaging
of luciferase bioluminescence (Figure 5C, inset). To con-
firm the adhesion result, we analyzed the effects of BST-
2 knockdown on adhesion to the extracellular matrix
Figure 5 Elevated mammary tumor cell BST-2 regulates cancer cell adhesion. PKH67Green-labeled BST-2-expressing shControl and BST-2-
suppressed sh137 and sh413 E0771 cells were allowed to adhere to murine embryonic fibroblasts (MEFs). (A) Representative confocal images of
adhered cells and (B) Image J quantification of PKH67Green + cells per field (n = 5) are shown. Images were taken at 20X. (C) Analysis of cancer
cell adhesion to MEF by quantification of luciferase bioluminescence shControl and sh413 cells. Luciferase assay quantified expression represented
as relative light units (RLU) and images (inset) were taken with the IVIS three-dimensional optical imaging system and analyzed with Living Image
Software. (D) Representative images and (E) quantification of shControl and sh413 4T1 cells adhered to collagen-coated plates. (F) Representative
images and (G) quantification of shControl and sh413 4T1 cells adhered to fibronectin-coated plates. Images were taken at 10X. Experiments
were performed multiple times with similar results. Error bars represent standard deviations and significance was taken at P <0.05*, <0.01**.
ns = not significant.
Mahauad-Fernandez et al. Breast Cancer Research  (2014) 16:493 Page 11 of 17(ECM) supportive substrates collagen and fibronectin [34]
using pre-coated plates. As expected, BST-2-suppressed
sh413-expressing 4T1 cells had reduced adhesive capabil-
ity to collagen (Figure 5D and E) and fibronectin (Figure 5F
and G) compared to BST-2-expressing shControl cells.
These results indicate that BST-2 regulates adhesion of
breast cancer cells to CAFs and to ECM proteins.
BST-2 depletion reduces anchorage-independent growth
Adaptation to new environment is a hallmark of aggres-
sive tumors. To survive, cancer cells are able to grow and
expand in the absence of attachments by overcoming
anoikis [35]. Because BST-2-expressing shControl cells
metastasized more efficiently than BST-2-suppressed
sh413 cells in vivo (Figure 3), we used a soft agar colony
formation assay to examine the possibility that BST-2 isimportant for anchorage-independent growth of mam-
mary cancer cells. As expected, we observed reduced col-
ony numbers (Figure 6A) and colony size (Figure 6B) in
mammary cancer cells with suppressed BST-2 (intermedi-
ate-sh137 and low-sh413) compared to cells expressing
high BST-2 (shControl). MCF-7 cells, known to form
colonies [36,37], were used as positive control (Figure 6C
and D) while normal human (HMLE) and murine
(NMuMG) mammary epithelial cells were used as negative
controls (Figure 6C and D). Interestingly, overexpression of
BST-2 in low BST-2-expressing MCF-7 cells (Figure S5A
in Additional file 5) increased MCF-7 colony size relative
to empty vector control (Figure S5B and S5C in Additional
file 5). These data suggest that suppression of BST-2
expression may diminish in vivo tumorigenicity of
otherwise highly tumorigenic cancer cells by reducing
Figure 6 Suppression of BST-2 expression in cancer cells results in anchorage-independency. (A and C) Quantification of the number of
colonies formed in soft agar by BST-2-expressing shControl, BST-2-suppressed sh137 and sh413 murine cells, MCF-7 (positive control), HMLE and
NMuMG cells following a 20-day transformation assay. The bar represents number of colonies per field (n = 5) for each cell type. Error bars correspond
to standard deviations. Significance was taken at P <0.001**. (B and D) Representative images of crystal violet-stained colonies from a soft agar assay
showing anchorage-independent growth of cancer cells. Clones were imaged at 4X. Experiments were repeated multiple times with similar results.
ns = not significant.
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expansion of tumor cells, invasion to adjacent tissues, and
dissemination throughout the body.
BST-2 expression promotes cancer cell migration and
invasion
Following the formation of primary tumors, a subpopula-
tion of cancer cells acquires a metastatic phenotype that
allows them to migrate to distant tissues [38]. Our in vivo
study revealed that expression of BST-2 may promote
tumor growth at secondary sites (Figure 3). Because cancer
cell migration and invasion are key to metastasis, including
dissemination of tumor cell into the lymphatic and blood
vessels, and subsequent extravasation of tumor cells into
secondary organs [39,40], we evaluated the effect of BST-2
on cancer cells migration using classical migration scratchassay with the cell comb scratch assay. Cancer cells sup-
pressed of BST-2 (sh137 and sh413) lost their ability to mi-
grate to the scratched wounds compared with those
expressing BST-2 (shControl) at both 6 h and 24 h time
points (Figure 7A and B). The rate of cell migration into
the wound opening was reduced in line with level of BST-
2 expression, thus, sh137 cells showed some migration
(Figure 7A, column 2, Figure 7B) while sh413 cells lost the
ability to migrate (Figure 7A, column 3, Figure 7B). The
rate of migration was quantified by blind-counting of at
least five different fields. In parallel, we performed migra-
tion assay on MCF-7 cells overexpressing BST-2. MCF-7
cells overexpressing BST-2 had higher migratory rate
compared to vector control cells (Figure S5D in Additional
file 5). These results show that the rate of cancer cell mi-
gration is strongly associated with BST-2 levels.
Figure 7 Endogenous BST-2 expressed in mammary cancer cells controls cell migration and invasion. (A) Representative images of cell
migration performed by scratch assay. Suppression of BST-2 expression by sh137 and sh413 reduced rate of cancer cell migration into the scratch
wound. (B) Quantification of cells that migrated into the scratch wound at 0, 6, and 24 h. (C) Migration assay by Boyden chamber. Representative
images taken at 4X. (D) Migrated cells were imaged and the number of migrated cells counted with Image J. Similar results were obtained with
4T1 shControl and sh413 cells. (E) BST-2-expressing shControl and BST-2 suppressed sh137 and sh413 E0771 cells and (F) shControl and sh413
4T1 cells were plated in low-serum medium on Matrigel-coated cell inserts and allowed to migrate for 24 h. Cells were stained with Giemsa stain.
Representative images taken at 20X are shown. (G) Quantification of cells that invaded through Matrigel. Cells from five different fields were
counted and averaged. Error bars corresponds to standard deviations. Significance was taken at P <0.001** and P <0.05*. Experiments were
repeated multiple times with similar results.
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migration, we employed commercially available Boyden
chamber assays. Equal numbers of shControl, sh137, and
sh413-expressing cells were plated in the apical chamber
of cell culture inserts. Serum-containing medium was
added to the basolateral chamber. Compared to cells
with high BST-2 expression (shControl), suppression of
BST-2 with sh137 and sh413 significantly reduced rate
of cell migration (Figure 7C and D).
Although BST-2 increased rate of cell migration into the
scratch wound, we found no BST-2-dependent difference
in rate of wound closure at 6 h and 24 h time points, sug-
gesting that cells with high (shControl) and suppressed
BST-2 (intermediate-sh137 and low-sh413) expression
may proliferate equally. Indeed, proliferation assay exam-
ining rate of BrdU incorporation into cells showed thatendogenous BST-2 had no effect on cell proliferation
(Figure S6A and S6B in Additional file 6). This result is in
contrast with a previous study that showed that exogenous
overexpression of BST-2 promotes cell proliferation [21]. It
is likely that the differences in results are due to different
experimental systems or cells. In our study, the lack of
BST-2 effect on cell proliferation, upon BST-2 knockdown,
may not be due to cell viability because metabolic activity
of MTT revealed that both BST-2-expressing and BST-2-
suppressed E0771 cells were equally viable (Figure S6C in
Additional file 6). However, in 4T1 cells, BST-2 knockdown
increased cell viability (Figure S6D in Additional file 6).
These data suggest that the effects of BST-2 in colony for-
mation and migration (Figures 6 and 7, respectively) can-
not be explained by differences in cell viability or cell
proliferation in vitro. Although we did not observe BST-2-
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ture, we cannot rule out the possibility that BST-2 may
promote cell proliferation in soft agar or in vivo.
In order to metastasize, cancer cells have to migrate and
invade the basement membrane. Hence we investigated
the ability of BST-2 to promote cancer cell invasion using
a Matrigel model. BST-2-expressing (shControl) and BST-
2-suppressed (intermediate-sh137 and low-sh413) cells
were allowed to invade into the Matrigel for 24 h. As
shown in Figure 7E, F, and G, significantly higher numbers
of BST-2-expressing shControl cells invaded into the
Matrigel compared to BST-2-suppressed sh137 and sh413
cells in that order. An enhancement in cancer cell invasion
also resulted when BST-2 was overexpressed in MCF-7
cells (Figure S5E in Additional file 5). These experiments
demonstrate that BST-2 expression is crucial for cancer
cell invasion and that suppressing BST-2 expression in
cancer cells reduced the ability of the cells to invade the
basement membrane.
Discussion
Host innate immune response is critical for surveillance
against pathogens and tumors. However, genes involved
in immune response may serve as a double-edged sword
in pathogenesis and tumorigenesis. As an innate immun-
ity antiviral gene, BST-2 positively regulates NF-кB acti-
vation [14,15] and its expression is induced by types I
and II interferons [16]. Increased expression of BST-2
retains budding viruses to the cell plasma membrane
[15,16] and inhibits virus replication [17,41]. However,
elevated levels of BST-2 in cancer cells have pro-tumor
functions [10,20]. In this study, we demonstrated that
BST-2 expressed in cancer cells promoted breast cancer
development and progression by altering the behavior of
cancer cells. Meta-analysis of TCGA (BRCA) human
data that showed that BST-2 is most significantly associ-
ated with luminal B tumors, invasive ductal carcinoma,
and metastatic tumors imply that BST-2 in cancer cells
could be a prognostic factor for highly aggressive can-
cers. It is known that luminal B tumors are associated
with larger tumor mass [42] and patients bearing this
tumor subtype have significantly worse disease-free sur-
vival compared to patients with luminal A tumors [43].
In our meta-analysis study, we found that human breast
tumors with elevated BST-2 mRNA are larger, more ag-
gressive, and patients bearing such tumors have poorer
survival. This association study was validated in our
mouse model experiments.
Mouse models have contributed to understanding breast
oncogenesis [30]. In our studies, we used two syngeneic
mouse models to allow investigation of the contribution of
cancer cell BST-2 in mammary tumorigenesis in different
backgrounds in the context of an intact immune system.
Implantation of BST-2-expressing 4T1 or E0771 cells intosyngeneic BALB/c or C57BL/6 mice respectively revealed
that BST-2 in cancer cells is disease modifying. However,
suppressing BST-2 expression decreased the onset of pri-
mary mammary tumor growth thereby increasing tumor
latency, and decreasing tumor cell metastases and growth
at distal sites, as in lung colonization.
Whether the decrease in metastasis observed in mice
bearing tumors from BST-2 suppressed cells is a direct
result of reduced tumor size or delayed metastasis is un-
known. However, our in vitro studies that showed that
cells with suppressed BST-2 have reduced adhesion,
anchorage-independent growth, migration, and invasion
supports a role for BST-2 in promoting tumor growth at
distal sites, because these cancer cell behaviors are crit-
ical for metastasis [39,40]. In addition, the lack of correl-
ation between formation of primary tumor and lung or
intestinal/mesentery colonization in our mouse model
suggests that BST-2 may differentially promote tumor
growth at the primary and secondary sites.
In addition to increased tumor growth at the primary
and secondary sites, mice bearing BST-2-expressing 4T1
shControl cells developed malignant ascites and spleno-
megaly or ascites and shock in the case of E0771 shCon-
trol cells-bearing mice. Ascites in tumor-bearing mice
may result from the accumulation of fluid in the peri-
toneal cavity due to the spread of cancer cells [44]. Asci-
tes is associated with increased vessel permeability and
decreased lymphatic drainage [45]. Indeed, human pa-
tients with cancer-associated ascites have poor prognosis
[46]. It is intriguing that BST-2-suppressed sh413-
injected mice had a delayed occurrence (E0771 cells) or
absence (4T1 cells) of ascites.
Aside from ascites, mice implanted with 4T1 BST-2-
expressing cells but not BST-2-suppressed cells developed
severe splenomegaly with expanded splenic red pulp, sug-
gestive of increased granulopoiesis. In mice, the spleen is a
normal site of hematopoiesis and reactive hematopoiesis.
Thus, the splenic granulocytic hyperplasia in shControl
mice is the result of reactive hematopoiesis secondary to
granulocyte recruitment to the site of tumor. In humans,
splenomegaly can be the result of extramedullary hema-
topoiesis (the spleen is not a normal site of hematopoiesis
in humans) but more commonly a result of cancer cell
metastases due to hematogenous disease [47]. Malignant
ascites and splenomegaly are manifestations of end-stage
events in many cancers including breast cancers [48,49]
and is linked to poor prognosis in tumor-bearing hosts.
BST-2 expression in tumor tissues is positively associ-
ated with hosts’ survival. In mice, tumors induced by
BST-2-expressing shControl cells were associated with
poor survival. The observed difference in survival be-
tween 4T1 cells and E0771 cells models could be attrib-
uted to (i) the level of aggressiveness of the cells; with
E0771 cells being more metastatic [29] than 4T1 cells
Figure 8 Schematic portraying the role of cancer cell intrinsic BST-2 in mammary cancer development. Red arrows portray elevated
expression. Blue arrows depict suppressed expression.
Mahauad-Fernandez et al. Breast Cancer Research  (2014) 16:493 Page 15 of 17[30], and (ii) the level of BST-2 in the different cancer
cells. We found that, BST-2 expression increased with
tumor aggressiveness in human patients. BST-2 expres-
sion was highest in the highly aggressive IDC compared
to DCIS tumors. Moreover, metastatic tumors expressed
more BST-2 than primary tumors.
Although the source of elevated BST-2 in breast tu-
mors is unknown, our data suggest that BST-2 expres-
sion in breast epithelial cells derived from breast tumors
was significantly higher than BST-2 in normal breast
epithelial cells. However, BST-2 expression between stro-
mal cells (tumors versus normal breast tissues) was not
different, indicating that tumor epithelial cells could
partly be contributory to elevated BST-2 in tumor tis-
sues. Therefore, BST-2 upregulation may be an import-
ant step in a series of changes that tumor cells undergo
during transformation.
Intriguingly, we found that the cellular mechanisms re-
sponsible for the tumorigenic potential of BST-2 include al-
terations in cancer cell adhesion, anchorage-independency,
migration, and invasion, but not proliferation. In two-
dimensional culture, suppression of BST-2 in murine
cancer cells had no effect on cell proliferation despite de-
creased ability of these cells to grow independent of an-
chor. Although not tested in this study, it is possible that
suppression of BST-2 may result in decreased proliferation
and increased susceptibility to apoptosis in vivo. However,
in two-dimensional culture, we found that 4T1 cells but
not E0771 cells with suppressed BST-2 expression have
higher viability as measured by MTT assay, indicating that
cell viability may not be implicated in the role of BST-2 in
cancer cell behavior. The attribute of BST-2 that endows it
the ability to simultaneously promote so many different
malignant processes is yet to be discovered.
It is possible that the expression of BST-2 provides cancer
cells a suitable milieu for their growth and spread through
the following processes: (i) alteration of cancer cell stiffness
enhancing cancer cell adhesion to extracellular matrix and
escape from primary tumor [50,51]; (ii) heightened NF-кBactivity and conversion of NF-кB-induced inflammatory
stimuli into tumor growth and metastatic signals; (iii) pro-
motion of cancer cells secretion of soluble signaling mole-
cules that potentiate tumor growth and metastasis; and (iv)
synthesis of endopeptidases such as matrix metallopro-
teinases to facilitate degradation of various components of
the extracellular matrix, thereby promoting tumorigenesis.
Further investigations are required in this respect.Conclusions
The results of this study as summarized in our model
(Figure 8) reveal the critical role of BST-2 in the many
processes involved in mammary oncogenesis by showing
that BST-2 expressed in carcinoma cells is a positive dis-
ease modifier and elevated levels of BST-2 predict tumor
aggressiveness and host survival. The inability of mam-
mary cancer cells with suppressed BST-2 to efficiently
colonize independent of attachment, along with the ob-
served increase in tumor latency in mice implanted with
BST-2-suppressed cells suggest that BST-2 action may
be early and sustained in the process of mammary
tumorigenesis. This report highlights the importance of
cell-intrinsic BST-2 in the emergence of neoplasia and
malignant progression of breast cancer. Therefore, BST-
2 may serve as a biomarker for aggressive breast cancers
and as a potential target for the development of new
therapeutics for BST-2-dependent cancers.Additional files
Additional file 1: Figure S1. BST-2 expression in human breast cancer cell
lines. (A) Expression of BST-2 mRNA from normal mammary epithelial cells
(HMLE), luminal A MCF-7 tumorigenic cells, and claudin-low MDA-MB-231
tumorigenic cells as determined by RT-qPCR. (B) BST-2 surface expression from
HMLE, MCF-7 and MDA-MB-231 cells as determined by flow cytometry. Numbers
in parenthesis correspond to BST-2 expression presented as a percentage.
All RT-qPCR data are normalized to GAPDH and presented as fold change over
HMLE. Error bars represent standard deviations and significance was taken at
P <0.01**. Experiments were repeated multiple times with similar results.
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is suppressed by BST-2-targeting shRNAs. (A) Expression of BST-2 mRNA
is higher in murine mammary tumor tissues and cells (E0771luc and
4T1luc) compared to normal mammary gland tissues as determined by
RT-qPCR. Following stable transduction of E0771luc and 4T1luc cells with
lentiviruses expressing different BST-2-targeting (sh137 and sh413) and
non-targeting (shControl) shRNA, levels of BST-2 (B and C) mRNA expression
were measured by real-time quantitative PCR, (D) surface protein expression
was measured by flow cytometry (FACS) and (E) total BST-2 protein was
measured by Western blot. Numbers correspond to band quantifications.
Percent (%) gene expression is calculated as BST-2/GAPDH*100. All RT-qPCR
data are normalized to GAPDH and presented as fold change over Normal
tissue or shControl cells. Error bars represent standard deviations and
significance was taken at P <0.01**.
Additional file 3: Figure S3. BST-2 downregulation decreases E0771
cell dissemination and growth in vivo. (A) Knockdown of endogenous
BST-2 expression in E0771 cells increases tumor latency. (B) Representative
images of tumor cells tracked in vivo with IVIS imaging system at different
time points. Images show higher luciferase bioluminescence in shControl
E0771-injected mice compared to sh413-injected mice. (C) Representative
luciferase bioluminescence accompanied with abdominal and
gastrointestinal tract (GI tract) gross images of uninjected (upper panel),
shControl-implanted (middle panel), and sh413-implanted mice (lower
panel). Arrow heads point to GI tumors. (D) Number of secondary tumors in
intestine/mesentery plotted as average of all mice. (E) Percent incidence
of liver and lung metastases. Error bars represent standard deviations and
significance was taken at P <0.01**.
Additional file 4: Figure S4. BST-2 expression in cancer cells predicts host
survival. (A) Clinical score plot of mice implanted with BST-2-expressing E0771
shControl and BST-2-suppressed sh413 cells. Clinical signs were scored as
follows: 0 = no abnormal clinical signs; 1 = ruffled fur but lively; 2 = ruffled fur,
activity level slowing, sick; 3 = ruffled fur, eyes squeezed shut, hunched, hardly
moving, very sick; 4 =moribund; 5 = dead [23]. (B) Representative images of
the abdomen and feet of uninjected, shControl, and sh413 C57BL/6 mice
implanted with E0771 cells. Arrow points to metastatic ascites (upper-middle
panels) and shock (lower-middle panel). (C) Kaplan-Meier survival plot of
mice implanted with BST-2-expressing shControl and BST-2-suppressed sh413
E0771 cells. Number corresponds to P value. Error bars represent standard
deviations. Median overall survival (OS) time and the area under the curve
(AUC) for each group are shown.
Additional file 5: Figure S5. Figure S5 BST-2 overexpression enhances
anchorage-independency, cancer cell migration, and invasion. (A) Expression
of BST-2 mRNA from MCF-7 cells stably transfected with an empty plasmid
(Vector) or with a BST-2-expressing plasmid (WT BST-2) as determined by
RT-qPCR. (B) Representative images of colonies from a soft agar assay
showing anchorage-independent growth of MCF-7 cells. Clones were
imaged at 10X. (C) Vector-expressing MCF-7 cells form smaller colonies
compared to BST-2-expressing MCF-7 cells. Data is presented as percent
normalized to Vector-expressing cells. (D) Representative images of cell
migration by Vector and WT BST-2 expressing cells and Image J quantification
of migration events (bars). (E) BST-2-expressing and Vector-expressing MCF-7
cells were plated in Matrigel-coated cell inserts and allowed to invade for
24 h. Cells were stained with Giemsa stain. Representative images taken at
20X and Image J quantification of invasion events (bars) are shown. Error bars
corresponds to standard deviations. Significance was taken at P <0.001** and
P <0.05*. ns = not significant.
Additional file 6: Figure S6. Endogenous BST-2 has no effect on
proliferation of mammary cancer cells. (A and B) BrdU incorporation assay
performed on shControl, sh137, and sh413 E0771 and 4T1 cells respectively.
Absorbance was measured at 450 nm using a Tecan Infinite M200 Pro plate
reader or cells were imaged using a Zeiss 710 confocal microscope (only for
E0771 cells). Images were processed using Image J software. (C and D)
MTT metabolism assay performed on shControl, sh137, and sh413 E0771
and 4T1 cells to determine cell viability. Absorbance was read at 590 nm
using a Tecan Infinite M200 Pro plate reader. Results are expressed as the
means ± standard deviations of optical density (OD). BrdU (green), BST-2
(red), and DAPI (blue). Error bars represent standard deviations. Significance
was taken at P <0.05*. ns = not significant. Experiments were repeated
multiple times with similar results.Abbreviations
7-AAD: 7-aminoactinomycin D; APC: allophycocyanin; AUC: area under the
curve; BRCA: breast-invasive carcinoma; BrdU: bromodeoxyuridine or 5-bromo-
2′-deoxyuridine; BSA: bovine serum albumin; BST-2: bone marrow stromal
antigen 2; CAFs: cancer-associated fibroblasts; CD317: cluster of differentiation
317; DAPI: 4′,6-diamidino-2-phenylindole; DCIS: ductal carcinoma in situ;
ECM: extracellular matrix; FACS: fluorescence-activated cell sorting; FBS: fetal
bovine serum; FITC: fluorescein isothiocyanate; GEO: Gene Expression Omnibus;
H&E: hematoxylin and eosin; HER2: human epidermal growth factor receptor 2;
IDC: invasive ductal carcinoma; IgG: immunoglobulin G; MEF: murine embryonic
fibroblast; NF-кB: nuclear factor kappa binding; OS: overall survival;
PBS: phosphate-buffered saline; PFA: paraformaldehyde; RPMI: Roswell Park
Memorial Institute medium; shRNA: short hairpin RNA; TCGA: The Cancer
Genome Atlas; TV: tumor volume.
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